Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumours.

Next Previous
Trial Profile

ANGIOCOMB Antiangiogenetic therapy for pediatric patients with brain stem tumours.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 19 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Celecoxib (Primary) ; Etoposide (Primary) ; Thalidomide (Primary)
  • Indications Brain cancer
  • Focus Therapeutic Use
  • Acronyms Angiocomb

Most Recent Events

  • 18 Sep 2022 Status changed from recruiting to completed.
  • 27 Dec 2012 Additional lead trial centers identified as reported by ClinicalTrials.gov.
  • 27 Dec 2012 Planned number of patients changed from 10 to 50 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top